文献速递神经康复儿童康复

持续鞘内巴氯芬治疗脑瘫儿童五年ICF-CY变化回顾性队列研究

Five-Year Retrospective Cohort Study of Changes in the International Classification of Functioning, Disability and Health of Children and Youth Parameters in Cerebral Palsy Children and Adolescents With Continuous Intrathecal Baclofen Therapy Versus Control Group.
PubMed 文献 · Am J Phys Med Rehabil · 2025-09-01

这项单中心5年回顾性队列研究分析了24例GMFCS IV-V级8-18岁脑瘫儿童,比较12例接受持续鞘内巴氯芬治疗与12例因禁忌症接受常规治疗者的ICF-CY变化。结果显示鞘内巴氯芬组在12个月及5年随访中改善痉挛、疼痛和BMI z评分,并在结构与功能、自主性和参与方面短期和长期均获益。

要点

  • 鞘内巴氯芬组在12个月及5年随访中改善痉挛、疼痛和BMI z评分。
  • 鞘内巴氯芬组在结构与功能、自主性和参与方面短期和长期均获益。
  • ICF-CY结局指标显示痉挛与无力及疾病进展之间存在相互关系。

核心结论

  • 持续鞘内巴氯芬治疗在短期和长期均改善脑瘫儿童的结构与功能、自主性和参与。
  • 鞘内巴氯芬组相比继续常规治疗的对照组从治疗中显著获益。

研究设计与样本

  • 5年单中心回顾性队列研究,纳入24例GMFCS IV-V级8-18岁脑瘫儿童,其中12例接受持续鞘内巴氯芬治疗,12例因禁忌症接受常规治疗。

主要发现

  • 鞘内巴氯芬组在12个月及5年随访中改善痉挛、疼痛和BMI z评分。
  • 鞘内巴氯芬组与对照组呈现不同的ICF-CY变化趋势。
  • ICF-CY结局指标显示痉挛与无力及疾病进展在儿童至青春期存在相互关系。

关键数值与推荐

  • 鞘内巴氯芬以最大140 μg/d、浓度2000 μg/mL持续简单给药。

临床怎么用

  • 对GMFCS IV-V级脑瘫儿童,持续鞘内巴氯芬治疗可作为改善痉挛、疼痛及ICF-CY相关结局的长期治疗选择。
  • 长期收集ICF-CY数据对比较治疗效果、实现个体化治疗和生活质量评估至关重要。

局限性

  • 单中心回顾性队列研究,样本量24例,对照组因禁忌症排除而非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to compare the long-term results of continuous intrathecal baclofen therapy rehabilitation against those of conventional treatment for intractable spasticity in children with cerebral palsy using the International Classification of Functioning, Disability and Health of Children and Youth. DESIGN: This is a 5-yr single-center retrospective cohort study. RESULTS: The International Classification of Functioning, Disability and Health of Children and Youth data from 24 patients with cerebral palsy of Gross Motor Function Classification System levels IV-V (aged between 8 and 18 yrs) were retrospectively analyzed for 5 yrs. The results show different trends between the 12 patients who received continuous intrathecal baclofen therapy and the 12 who were excluded because of contraindications.The continuous intrathecal baclofen therapy group improved spasticity, pain, and body mass index z-scores over 12 mos and during the 5-yr follow-up with a continuous simple Baclofen administration at a maximum of 140 μg/d at a concentration of 2000 μg/mL. CONCLUSIONS: Continuous intrathecal baclofen therapy improves structure and function, autonomy, and participation in both short and long term. Overall, the continuous intrathecal baclofen therapy group, with its characteristics of initially greater pain and hypertonia, benefited significantly from the efficacy of intrathecal Baclofen treatment compared with the control group, which continued to receive conventional treatment.The International Classification of Functioning, Disability and Health of Children and Youth outcome measures demonstrated an interrelationship between spasticity and weakness and disease progression over childhood to adolescence.Follow-up will be vital for effective personalized treatment, quality of life, and research.Long-term International Classification of Functioning, Disability and Health of Children and Youth data collection is key to comparing treatment outcomes.

来源:Am J Phys Med Rehabil,查看原文。版权归原作者所有。

引用

  1. Ronchetti AB, Biasotti G, Pistorio A, et al. Five-Year Retrospective Cohort Study of Changes in the International Classification of Functioning, Disability and Health of Children and Youth Parameters in Cerebral Palsy Children and Adolescents With Continuous Intrathecal Baclofen Therapy Versus Control Group. Am J Phys Med Rehabil. 2025. PMID: 40907949. doi:10.1097/PHM.0000000000002770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。